In­cyte changes man­u­fac­tur­ing process, adds sec­ond site to solve Opzelu­ra tex­ture is­sue

From the start of In­cyte’s Q1 earn­ings call, the man­u­fac­tur­ing is­sues sur­round­ing Opzelu­ra were ad­dressed by Hervé Hop­penot, the com­pa­ny’s CEO. And though is­sues have slowed the treat­ment back, the phar­ma said it added a sec­ond man­u­fac­tur­ing site to pro­duce the atopic der­mati­tis drug, and im­ple­ment­ed a new process af­ter gain­ing FDA ap­proval.

“Con­sis­tent with best prac­tices, we have re­ceived FDA ap­proval for a sec­ond man­u­fac­tur­er of Opzelu­ra to sup­port our suc­cess­ful launch,” he said, be­fore hand­ing things over to US gen­er­al man­ag­er Bar­ry Flan­nel­ly. “We are al­so prepar­ing to rein­tro­duce sam­ples in the US.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER